Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Crocs

First American Financial

Meritage Homes

Sonic Automotive

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Relative Price Strength Make These 5 Stocks Worth a Look Now

Industrial Logistics Properties

Medpace Holdings

Telephone and Data Systems

Unitil

As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.

5 Stocks to Buy on a Possible Second Rate Cut in September

DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.

DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2

DaVita Inc. (DVA) CEO Javier Rodriguez on Q2 2019 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 10.91% and -0.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q2 Earnings Top Estimates

Centene

Canadian Solar

Legg Mason

SYNNEX

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

6 Promising Price-to-Book Value Stocks to Buy in August

DaVita (NYSE: DVA) announces its next round of earnings this Thursday, August 1. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.

Earnings Preview For DaVita

Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.

DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat

DaVita's latest news includes a 5.2% gain for DVA stock as the business increases its forecast for its fiscal 2019. Here's what is relevant.

DaVita News: DVA Stock Soars on Upbeat Guidance

Davita Inc (NYSE: DVA) expects income for the second quarter to be between $460 million-$465 million and raised 2019 adjusting operating income guidance from $1.54 billion-$1.64 billion to $1.64 billion-$1.70 billion.

Davita Trades Higher After Raising Guidance

Shares of DaVita Inc. DVA, -1.22% rallied 4.2% in premarket trading Monday, after the dialysis services company raised its profit outlook, as it looks to update investors ahead of the expected modified "Dutch auction" to buy back up to $1.2 billion worth of its shares.

DaVita's stock rallies after profit outlook raised

CVS Health

Fresenius Medical Care

CVS Health began a trial of a home dialysis system that could cut into a market controlled by Fresenius Medical and DaVita. But all three stocks fell.

CVS Health Tests Home Dialysis System; DaVita, Fresenius Hit

Amgen

Baxter

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Trump's Order on Kidney Care Lifts These Dialysis Stocks

Advanced Micro Devices

Honeywell

The stock charts of Davita, Honeywell and Advanced Micro Devices are being shaken and stirred into a trade-worthy situation.

3 Big Stock Charts for Thursday: Davita, Honeywell and Advanced Micro Devices

The details of the proposal for achieving that goal appear to be far less threatening to the major dialysis providers than initially feared by many investors.

Kidney dialysis stocks soar as investors see Trump executive order as good news

CareDx

President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.

Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others

American Renal Associates Hlds

Shares of DaVita Inc.  bounced 4.3% in afternoon trading Wednesday, after President Trump signed an executive order on kidney disease, aimed at cutting costs of dialysis treatments.

DaVita, American Renal stocks bounce after President Trump signs executive order on kidney disease

The executive order would create new payment models to encourage more kidney transplants and give patients incentives to seek dialysis treatment at home instead of at more expensive treatment centers, HHS Secretary Alex Azar says.

Trump to sign executive order overhauling kidney transplant, dialysis market

Liberty Oilfield Services

AquaVenture Holdings

Companies raising cash were among the hardest hit Tuesday.

Why DaVita, AquaVenture Holdings, and Liberty Oilfield Services Slumped Today

I've held DaVita on and off for many of the past 7 years.

DaVita: A Marriage On The Test Bed

The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.

DaVita Divests DMG to Optum, Boosts Kidney Care Services

UnitedHealth Group

The Federal Trade Commission said late Wednesday UnitedHealth Group Inc. and DaVita Inc. have agreed to a settlement to resolve FTC allegations their $4.3 billion deal would stifle competition in the Las Vegas area.

U.S. trade regulator approves United Health, DaVita deal with condition

Optical Cable

Berkshire Hathaway Chairman and CEO Warren Buffett (Trades, Portfolio) has been unable to praise his hires to succeed him at portfolio management, Ted Weschler and Todd Combs, highly enough.

Ted Weschler Stocks

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Why Is DaVita HealthCare (DVA) Down 9.9% Since Last Earnings Report?

Clorox

Expedia

The stock charts of DVA, EXPE and CLX stock are primed to start the new trading week on a trade-worthy foot.

News for DaVita Stock (DVA)